Daidzin

Daidzin

Identity and Chemical Characterization

Daidzin is a naturally occurring isoflavone glycoside and the primary dietary form of its aglycone, daidzein. It is identified chemically as the 7-glucoside of 4′,7-dihydroxyisoflavone and is isolated most abundantly from Radix puerariae (kudzu root). Its molecular formula is C₂₁H₂₀O₉, as registered in PubChem under CID 107971, and its IUPAC name is 7-(β-D-glucopyranosyloxy)-3-(4-hydroxyphenyl)-4H-chromen-4-one.

Daidzin is the 7-O-β-D-glucoside of daidzein; that is, a glucose molecule is attached via a β-glycosidic bond at the 7-hydroxyl position of the daidzein aglycone skeleton. Daidzein itself is commonly found in plants primarily in such a glycosylated form, where it is naturally abundant and usually exists as beta-glycosides; in humans, after ingestion, the aglycone circulates in the bloodstream in its free form.

Structurally, daidzein (the aglycone product) belongs to the isoflavone subclass of flavonoids. Daidzein is a naturally occurring compound found in soybeans and other legumes and belongs structurally to the isoflavones; isoflavones are produced in plants through the phenylpropanoid pathway of secondary metabolism and function as signal carriers and in defense responses to pathogenic attacks. Daidzein is derived from the shikimate pathway and forms an oxygen-containing heterocycle through a cytochrome P-450-dependent, NADPH-dependent enzyme.

Natural Sources

Daidzin is a naturally occurring isoflavone extracted from leguminous plants such as soybeans. It is also a major constituent of Pueraria lobata (kudzu). Daidzin is found in Radix puerariae (RP), an herbal medicine prepared from the root of the legume Pueraria lobata (kudzu), which has been used for centuries in traditional Chinese medicine to treat a variety of disorders including alcohol dependency.

Genistein, daidzein, and glycitein (and their different chemical forms) comprise approximately 50%, 40%, and 10%, respectively, of total isoflavone content in soy, although there is considerable variation among soybean varieties and soy foods. In soybeans and unfermented soy foods, isoflavones occur almost entirely as glycosides — meaning daidzin is the predominant form in which daidzein is found in raw and minimally processed soy products. Daidzein and other isoflavone compounds are present in a number of plants and herbs such as kwao krua (Pueraria mirifica), kudzu, and Maackia amurensis cell cultures.

Common Forms and Preparations

Daidzin and its aglycone daidzein are encountered in several chemical forms depending on the food matrix and processing method. In the soybean before processing, glucosylated isoflavones are esterified with malonic acid at the 6-hydroxyl position of the glucose moiety; processing to make soy foods may or may not retain this ester group — for example, soy foods made from defatted soy flour and then toasted will have the malonyl group decarboxylated to an acetyl group. In fermented soy foods, glucosyl groups are removed and modification of the isoflavone may have occurred.

The main dietary source of daidzein is the biologically active glucoside daidzin; fermentation or digestion of soybeans or soy products results in the release of the sugar molecule from daidzin, leaving the isoflavone aglycone, daidzein. Dietary supplement preparations containing daidzin include standardized kudzu root extracts (in capsule and tablet form) and soy isoflavone concentrate preparations. Daidzein intake is primarily through soy-based items or supplements that include daidzein itself or its glycoside variant, daidzin; the levels in soy products can vary based on the nature of the product, processing techniques, and culinary methods used during preparation.

Traditional and Historical Use

Traditional Chinese Medicine (TCM)

The first written mention of kudzu as a medicine is in the ancient herbal text of Shen Nong (circa A.D. 100). As early as approximately 600 A.D., Sun Simiao recorded the use of Radix puerariae to treat alcohol intoxication, and Li Dongyuan (~1200 A.D.) recorded its use for alcohol abuse. This places the earliest documented anti-alcohol application of daidzin-containing preparations roughly 1,000 years before modern scientific characterization of the compound.

In Traditional Chinese Medicine, kudzu root is used in prescriptions for the treatment of wei (superficial) syndrome — manifesting as mild fever — thirst, headache, and stiff neck with pain due to high blood pressure; it is also recommended for allergies, migraine headaches, and diarrhea. Radix puerariae has been used in traditional Chinese medicine for the treatment of fevers, gastrointestinal disorders, muscle aches, allergies, skin problems, high blood pressure, and chronic alcoholism.

Traditional Chinese medicine also utilizes daidzin to treat various diseases such as diarrhea, fever, hepatitis, and cardiac problems. The historical application for drunkenness has become a major focal point of modern research on kudzu, and in modern Chinese medicine it is also used as a treatment for angina pectoris.

Japanese Traditional Use

In Japan, kudzu is not primarily a dietary supplement but rather a food ingredient; its leaves are prepared in salads, its flowers made into tempura, and its roots used as a culinary thickener in powder form, mixed into various dishes. This culinary use has resulted in consistent dietary exposure to daidzin across Japanese populations over centuries, a fact that has informed modern epidemiological research on isoflavone health effects.

Key Constituents and Mechanisms of Action

Relationship Between Daidzin and Daidzein

Daidzin is the glycosylated precursor to the biologically active aglycone daidzein. In soy, isoflavones are found mostly as glycoside conjugates (daidzin, genistin, and glycitin); these β-glycosides have low estrogenic activity and must be hydrolyzed into bioavailable isoflavone aglycones (daidzein, genistein, and glycitein) before exerting their biological effects. The different chemical forms of soy isoflavones determine whether they undergo digestion by intestinal β-glucosidases and hence their uptake from the small intestine, as well as first-pass metabolism by bacterial β-glucosidases and other microflora in the large intestine.

ALDH-2 Inhibition: The Central Mechanism for Alcohol-Related Effects

The most extensively characterized mechanism of daidzin is its selective inhibition of mitochondrial aldehyde dehydrogenase (ALDH-2). Human mitochondrial aldehyde dehydrogenase (ALDH-I/ALDH-2) is potently, reversibly, and selectively inhibited by daidzin; kinetic analysis with formaldehyde as substrate reveals that daidzin inhibits ALDH-I competitively with respect to formaldehyde with a Ki of 40 nM, and uncompetitively with respect to the coenzyme NAD⁺. The human cytosolic aldehyde dehydrogenase isozyme (ALDH-II) is nearly three orders of magnitude less sensitive to daidzin inhibition.

Daidzin does not inhibit human class I, II, or III alcohol dehydrogenases, nor does it have any significant effect on biological systems that are known to be affected by other isoflavones. This high selectivity for ALDH-2 distinguishes daidzin from many other alcohol-aversive agents.

The crystal structure of daidzin in complex with ALDH-2 at 2.4 Å resolution shows the isoflavone moiety of daidzin binding close to the aldehyde substrate-binding site in a hydrophobic cleft, with the glucosyl function binding to a hydrophobic patch immediately outside the isoflavone-binding pocket. These observations explain both the specificity and affinity of daidzin (IC₅₀ = 80 nM) and the affinity of analogues with different substituents.

MAO–ALDH-2 Pathway and Monoamine Metabolism

Daidzin, described as a major active principle of an ancient Chinese herbal treatment (Radix puerariae) for alcohol abuse, selectively suppresses ethanol intake in all rodent models tested and inhibits mitochondrial ALDH-2; studies on ethanol intake suppression by structural analogues established a link suggesting daidzin suppresses ethanol intake by inhibiting ALDH-2, which is a principal enzyme involved in serotonin (5-HT) and dopamine (DA) metabolism, such that daidzin may act by inhibiting 5-HT and DA metabolism.

A link between daidzin's capacity to reduce alcohol consumption and its ability to increase the liver mitochondrial monoamine oxidase (MAO):ALDH-2 activity ratio has been established; daidzin analogs that potently inhibit ALDH-2 but not MAO are the most antidipsotropic, whereas those that also inhibit MAO are not; thus, the liver mitochondrial MAO-ALDH-2 pathway is proposed as the primary site of action of daidzin, with a biogenic aldehyde derived from MAO action mediating its antidipsotropic effect.

Phytoestrogenic / Selective Estrogen Receptor Modulator (SERM)-Like Activity

Isoflavones including daidzein (and thus daidzin as its precursor) are plant-derived compounds structurally similar to 17β-estradiol (E2) and capable of binding estrogen receptors; they exhibit selective estrogen receptor modulator (SERM)-like activity, favoring ERβ over ERα, which underlies their tissue-specific effects.

Equol: The Key Metabolite

After soy products are consumed, the bacteria of the intestinal microflora metabolize isoflavones to metabolites with altered absorption, bioavailability, and estrogenic characteristics; variations in the effect of soy products have been correlated with isoflavone metabolites in plasma and urine; the beneficial effects of daidzin, the glycoside of daidzein, have been reported primarily in individuals producing equol — a reduction product of daidzein produced by specific colonic bacteria — and these equol-producing individuals comprise 30% of populations consuming Western diets and 60% of populations consuming soy-rich Asian diets.

Equol is considerably more estrogenic than daidzein; it has been reported to be 100-fold more potent than daidzein in stimulating an estrogenic response, and equol is stronger than daidzein at competing with estradiol for binding to the estrogen receptor; it has also been demonstrated to be a more effective antioxidant than daidzein or genistein.

Antioxidant Activity

Daidzein's gut microbial metabolites O-desmethylangolensin (O-DMA), equol, and daidzin have antioxidant properties in the following sequence: daidzein > equol > O-DMA > daidzin. This indicates that while daidzin itself has measurable antioxidant capacity, its aglycone and key metabolite equol are more potent antioxidants.

Pharmacokinetics and Bioavailability

Some of daidzein's unfavorable physicochemical characteristics — poor solubility, low partition coefficient, and high intestinal and hepatic metabolism — lead to low oral bioavailability; animal model studies show the absolute bioavailability of a daidzein suspension after oral administration to rats was approximately 6.1%. In healthy premenopausal women, daidzein has been shown to have low bioavailability and non-linear pharmacokinetics with higher intakes, indicating that its absorption is rate-limited and becomes saturated.

Physiologically based pharmacokinetic (PBPK) model-based predictions for the maximum daidzein plasma concentration (Cmax) were comparable to literature data; the predictions also revealed that the Cmax of S-equol in equol-producers was only up to 0.22% that of daidzein, indicating that despite its higher estrogenicity, S-equol is likely to contribute to overall estrogenicity upon daidzein exposure to only a limited extent.

Pharmacokinetic studies reveal moderate bioavailability and interindividual variability due to gut microbiota metabolism. Daidzin itself is generally not directly absorbed; the glycosidic bond must first be cleaved. The different chemical forms of soy isoflavones determine whether they undergo digestion by intestinal β-glucosidases and hence their uptake from the small intestine, as well as first-pass metabolism by bacterial β-glucosidases and other microflora in the large intestine. Red clover and soy isoflavones have long half-lives of 13–23 hours, caused in part by enterohepatic recirculation; after phase II enzymatic sulfation or glucuronidation, isoflavone conjugates can be excreted into the bile, deconjugated by intestinal microbiota, and then reabsorbed.

Scientific Evidence by Area of Use

1. Alcohol Use Disorder and Reduction of Alcohol Intake

This is the most scientifically developed area of daidzin research, rooted in both traditional use and a clear biochemical mechanism.

Preclinical evidence (animal models): Daidzin selectively inhibits mitochondrial ALDH-2 and reduces alcohol intake in heavy drinking rodents; paradoxically, daidzin reduces heavy drinking in Golden Syrian hamsters without increasing acetaldehyde levels. Failure to increase acetaldehyde levels appears to be due to alternative metabolism of acetaldehyde by high levels of uninhibited cytosolic ALDH-1 in these hamsters; reducing drinking without elevating acetaldehyde suggests that additional pathways in the brain may be involved in the beneficial effect.

Traditional Chinese medicine has used the kudzu plant to treat alcohol use disorder and combat intoxication for centuries; research into protective mechanisms of this plant suggests that its flavonoids — including puerarin, daidzin, and daidzein — may inhibit the ALDH-2 pathway to decrease alcohol consumption.

Daidzin's activity mimics the effect of the naturally occurring ALDH-I genetic variant found among Chinese populations; daidzin selectively inhibits the low Km ALDH isozyme such that high levels of acetaldehyde are likely oxidized by the high Km isozyme (ALDH-II), suggesting that acetaldehyde accumulation will be limited to non-toxic levels — in contrast to disulfiram, which inhibits both ALDH-I and ALDH-II.

Clinical evidence: Direct, isolated clinical trials of daidzin alone in humans with alcohol use disorder are limited in the published literature. Research has largely been conducted using whole kudzu root extract, which contains puerarin, daidzin, and daidzein together. The historical application for drunkenness has become a major focal point of modern research on kudzu, and investigators at Harvard Medical School have studied kudzu extract formulations in small human trials. Evidence from kudzu extract trials suggests reduced alcohol intake in heavy drinkers, but these studies cannot isolate the effect of daidzin alone from that of other isoflavones such as puerarin. The evidence base for daidzin specifically in human alcohol use disorder remains preclinical and mechanistic; no large-scale randomized controlled trials of isolated daidzin have been published as of the present review.

2. Menopausal Symptoms and Hormonal Health

Clinical trials show that daidzein and genistein, especially in equol-producing individuals, can reduce vasomotor symptoms such as hot flashes and night sweats; while results across studies vary, consistent findings support their safety and modest efficacy, particularly for women unable or unwilling to use hormone replacement therapy. Because daidzin is the dominant dietary precursor to daidzein, these findings are directly relevant to daidzin intake.

At dietary levels, these compounds are generally safe, although high-dose supplementation is discouraged in individuals with hormone-sensitive cancers. The evidence for menopausal symptom relief from soy isoflavone preparations containing daidzin/daidzein is moderate but heterogeneous, with effect sizes depending substantially on equol-producer status.

3. Bone Health and Osteoporosis

Daidzein increases the expression of bone morphogenetic protein (BMP) in primary osteoblast cells, promoting osteoblast development, which has been associated with anti-osteoporosis activity in preclinical settings.

Studies have demonstrated the use of phytoestrogens — including genistein and daidzein — to effectively increase osteogenic activity of bone marrow-derived mesenchymal stem cells (BMSCs). In animal (ovariectomized mouse) models, daidzein treatment has been investigated for protection against estrogen deficiency-induced bone loss. It was demonstrated that daidzein improved migration and proliferation of bone marrow endothelial cells and improved H-type vessel formation through inhibition of caveolin-1, which suppressed EGFR/AKT/PI3K signaling; this study demonstrated that daidzein alleviates ovariectomy-induced osteoporosis by promoting H-type vessel formation in cancellous bone, which then promotes bone formation.

Daidzin resembles the structure of mammalian estrogen and is reported to regulate estrogenic activity in diseases such as breast cancer, osteoporosis, and cardiovascular diseases. Evidence for bone health effects of daidzin/daidzein in humans is preliminary; most supporting data derive from animal models and in vitro systems. Clinical trials of soy isoflavone formulations on bone mineral density in postmenopausal women have produced mixed results.

4. Cardiovascular Effects

Daidzein has shown potential beneficial effects regarding various cardiovascular diseases and risk factors; however, data are inconsistent; a review searched Scopus, PubMed, Google Scholar, and Web of Science to assess impacts on CVD across in vitro, animal, and clinical settings; in vitro and animal studies showed daidzein and daidzin are effective in terms of reducing inflammation, oxidative stress, hyperlipidemia, myocardial infarction, thromboembolism, hypertension, and aneurysms; however, clinical studies only confirmed a relatively small portion of previous in vitro and animal findings, including anti-hyperlipidemic effects.

Daidzein significantly raises high-density lipoprotein cholesterol (HDL-C) levels, lowers levels of circulating triglycerides (TGs) and low-density lipoprotein cholesterol (LDL-C), and thus may prevent heart attack or stroke — though these lipid effects are largely established in animal models and observational data, rather than confirmed in well-powered clinical trials specifically for daidzin. The overall cardiovascular evidence base for daidzin in isolation is weak and predominantly preclinical.

5. Anticancer Activity

In preclinical studies, daidzin induces oxidative stress, apoptosis, cytotoxicity, and cell cycle arrest while inhibiting proliferation, migration, invasion, and angiogenesis across various cancer cell lines, including breast, prostate, cervical, hepatocellular, and colon cancers.

Cell-based and in vivo studies showed that daidzin can inhibit the ability of osteosarcoma cells to proliferate and metastasize; combined treatment of daidzin and cisplatin showed further suppression in osteosarcoma cell viability, migration, and invasion ability compared to single treatment arms, and led to further apoptosis.

Daidzin is reported to have anticancer activity against prostate cancer cells, breast cancer, and colon and hepatic cancer in preclinical studies. Despite promising preclinical findings, the lack of clinical validation underscores the need for well-designed human trials to confirm efficacy and safety, paving the way for translational application in oncology. The anticancer evidence for daidzin is currently preclinical (in vitro and animal models) only; there are no completed clinical trials demonstrating anticancer efficacy of isolated daidzin in humans.

6. Neuroprotection

Daidzein aids in neuroprotection and functional recovery following a stroke, and has shown peroxisome proliferator-activated receptor gamma (PPAR-γ)-dependent therapeutic effects in brain cells. Research indicates that puerarin and daidzin may help protect nerve cells in stressful conditions; experimental studies show reduced oxidative damage and improved cell survival in models of brain injury and neurotoxicity; however, more clinical evidence is needed. The neuroprotective evidence for daidzin specifically is preliminary and restricted to preclinical models.

7. Metabolic Effects (Diabetes and Obesity)

Daidzein increases the ratio of glucose transporter-4 (GLUT4) to Na⁺/K⁺ ATPase levels, which facilitates glucose absorption and maintains the proper balance of reactive oxygen species to free radicals in preclinical settings. Evidence directly attributable to daidzin in human metabolic disease trials has not been established as a separate therapeutic entity. The current evidence is preliminary and primarily from animal and in vitro studies.

Body Systems Associated with Daidzin

• Hepatic/Alcohol Metabolism System: ALDH-2 inhibition influencing acetaldehyde and monoamine catabolism in the liver mitochondria.
• Endocrine System: Phytoestrogenic activity via ERα and ERβ binding, primarily ERβ-selective.
• Skeletal System: Modulation of osteoblast and osteoclast activity via estrogenic and BMP signaling pathways.
• Cardiovascular System: Potential anti-inflammatory, antioxidant, antilipidemic, and antithrombotic effects documented preclinically.
• Gastrointestinal/Microbiome: Conversion by colonic bacteria to daidzein and subsequently equol; variability in this conversion is a critical determinant of biological response.
• Central Nervous System: Preclinical evidence for neuroprotection and modulation of dopamine and serotonin metabolic pathways via ALDH-2.
• Oncological (preclinical): Multiple cancer cell lines affected through apoptosis, cell cycle arrest, and inhibition of key oncogenic signaling cascades (JAK2/STAT3, PI3K/Akt, Wnt/β-catenin).

Dosage Forms and Reported Dosages

Daidzin is not generally available as an isolated pharmaceutical agent in human clinical trials. It is most commonly consumed as:

• Dietary soy foods: Whole soybeans, tofu, soy protein concentrates, soy beverages, and fermented soy products (e.g., miso, tempeh), which naturally contain variable amounts of daidzin and daidzein.
• Standardized kudzu root extracts: Radix puerariae extracts standardized to isoflavone content (including daidzin and puerarin), available as capsules and tablets.
• Combined isoflavone supplements: Soy isoflavone preparations containing a mixture of daidzin, genistin, glycitin, and their aglycones.

One clinical pharmacokinetic interaction study tested a standardized red clover dietary supplement at 120 mg isoflavones per day in fifteen peri- and post-menopausal women to assess interactions with CYP probe substrates. This dose range (approximately 40–120 mg/day of total isoflavones) is representative of typical clinical trial dosages, though most such trials do not isolate daidzin from total isoflavone content.

In the ovariectomized mouse bone study referenced above, daidzein was used at a dose of 10.0 mg/kg/day for 6 weeks in Ovx mice to protect against trabecular microarchitecture loss. These preclinical doses are not directly translatable to human supplementation recommendations.

No single, well-validated human clinical dose for isolated daidzin has been established in the peer-reviewed literature. Dosages reported across soy isoflavone trials range broadly, and the fraction represented by daidzin specifically varies by product and preparation.

Safety Considerations and Drug Interactions

General Safety Profile

Radix puerariae, from which daidzin was isolated, has been used apparently safely in traditional Chinese medicine for two thousand years in a number of medical conditions; these facts suggest daidzin would be a direct, safe, effective, and reversible agent, without the significant toxic side effects consistently observed with chemically reactive compounds such as disulfiram and cyanamide.

At dietary levels, these compounds are generally safe, although high-dose supplementation is discouraged in individuals with hormone-sensitive cancers.

Estrogenic Activity at High Doses

With respect to daidzin, the only reported pharmacological activity beyond ALDH inhibition is its estrogenic activity at high doses. Given the SERM-like profile of its aglycone daidzein — which preferentially activates ERβ over ERα — the clinical significance of estrogenic activity at typical dietary intake levels is considered low, but remains a subject of ongoing investigation, particularly for hormone-sensitive conditions.

CYP450 Enzyme Interactions

Inhibition of nine forms of cytochrome P450 (CYP3A4, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2C9, CYP2D6, and CYP2E1) by twelve isoflavonoids — including daidzin and its aglycone daidzein — has been studied systematically. The most potent inhibitors of CYP enzymes were genistein and daidzein, inhibiting CYP2C9 and CYP3A4 noncompetitively; potent inhibition of CYP3A4 was also observed with biochanin A and equol. Daidzin (the glycoside itself) showed weaker CYP inhibition in these assays compared to its aglycone daidzein.

Although marketed as a safer alternative to hormone therapy, red clover isoflavones (including daidzein and related compounds) have been reported to inhibit some cytochrome P450 enzymes involved in drug metabolism. However, in the clinical study testing 120 mg/day of standardized red clover isoflavones, CYP interactions were not found to be clinically significant — suggesting that in vivo, at realistic supplemental doses, CYP inhibition by these isoflavones may not translate to meaningful drug interactions.

Drug Transporter Interactions

Daidzein, as the active aglycone derived from daidzin, has been shown in vitro to inhibit the drug transporter BCRP/ABCG2 in breast cancer cells. The phytoestrogens daidzein and equol inhibit the drug transporter BCRP/ABCG2 in breast cancer cells. The clinical significance of this interaction at typical dietary or supplemental daidzin doses has not been established.

Anticoagulant and Antithrombotic Considerations

Daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora, has been reported to have antithrombotic and antiallergic activities. This antithrombotic property raises theoretical concern for additive effects when combined with anticoagulant or antiplatelet drugs, though human clinical data confirming a meaningful interaction are not available in the reviewed literature.

Hormone-Sensitive Conditions

Given the phytoestrogenic activity of daidzin's metabolite daidzein, caution has been urged in the context of hormone-sensitive cancers. High-dose supplementation is discouraged in individuals with hormone-sensitive cancers. Emerging evidence suggests lifelong consumption of soy-based foods may reduce cancer risk at dietary intake levels, but the safety of high-dose isoflavone supplements in this context has not been definitively established.

Acetaldehyde Accumulation — Differences from Disulfiram

Because daidzin inhibits ALDH-2, there is a theoretical concern about acetaldehyde accumulation when alcohol is consumed concurrently. However, daidzin selectively inhibits the low Km ALDH isozyme; in its presence, high levels of acetaldehyde are likely oxidized via the high Km isozyme (ALDH-II), suggesting that acetaldehyde accumulation will be limited to non-toxic levels by ALDH-II — in contrast to the high and toxic levels of acetaldehyde that accumulate with disulfiram, which inhibits both ALDH-I and ALDH-II.

Summary of Evidence Strength

• Alcohol use disorder (mechanism and animal models): Strong mechanistic and preclinical evidence. Clinical evidence limited; isolated daidzin human trials are absent from the literature.
• Menopausal symptoms: Moderate clinical evidence for soy isoflavone formulations containing daidzin/daidzein; effects depend substantially on equol-producer status and vary across studies.
• Bone health: Preliminary; animal model and in vitro data are promising but human clinical evidence is mixed and limited.
• Cardiovascular effects: Weak in humans; in vitro and animal data are more consistent but clinical translation has not been demonstrated for daidzin specifically.
• Anticancer activity: Preclinical only; no human clinical trials for isolated daidzin in oncology have been published.
• Neuroprotection and metabolic effects: Very preliminary; restricted to animal and in vitro models.

References

• Ahmad et al. (2024). A review on daidzein as food supplement: Exploring its phytopharmacological and preclinical status. eFood, Wiley Online Library.
• Keung WM, Vallee BL (1993). Daidzin: a potent, selective inhibitor of human mitochondrial aldehyde dehydrogenase. PubMed (PNAS).
• Anticancer potential of daidzin: a comprehensive literature review. PubMed, 2025.
• Perspective: Isoflavones—Intriguing Molecules but Much Remains to Be Learned about These Soybean Constituents. PMC, 2025.
• Perspective: Isoflavones—Intriguing Molecules but Much Remains to Be Learned about These Soybean Constituents. ScienceDirect, 2025.
• Daidzein. Wikipedia.
• Keung WM et al. (1998). Daidzin and its antidipsotropic analogs inhibit serotonin and dopamine metabolism in isolated mitochondria. PubMed.
• Alcohol metabolism in alcohol use disorder: a potential therapeutic target. Alcohol and Alcoholism, Oxford Academic, 2023.
• Structure of Daidzin in Complex with Human Mitochondrial Aldehyde Dehydrogenase. Journal of Medicinal Chemistry, ACS.
• Anti-dipsotropic isoflavones: potential therapeutic agents for alcohol dependence. PubMed, 2003.
• Suppression of Heavy Drinking and Alcohol Seeking by a Selective ALDH-2 Inhibitor. PMC, 2021.
• Synthesis of potential antidipsotropic isoflavones: inhibitors of the mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway. PubMed, 2001.
• Use of Physiologically Based Pharmacokinetic Modeling to Predict Human Gut Microbial Conversion of Daidzein to S-Equol. PMC, 2022.
• Daidzein and Genistein: Natural Phytoestrogens with Potential Applications in Hormone Replacement Therapy. PMC, 2025.
• Unveiling the Pharmacological and Nanotechnological Facets of Daidzein: Present State-of-the-Art and Future Perspectives. PMC, 2023.
• The Role of Colonic Bacteria in the Metabolism of the Natural Isoflavone Daidzin to Equol. PMC.
• Dihydrodaidzein-producing Clostridium-like intestinal bacterium, strain TM-40, affects in vitro metabolism of daidzein. PMC, 2014.
• Transcriptional Regulation of the Equol Biosynthesis Gene Cluster in Adlercreutzia equolifaciens. PMC, 2019.
• Recent updates on daidzein against oxidative stress and cancer. PMC, 2019.
• Daidzin and its de-glycosylated constituent daidzein as a potential therapeutic for cardiovascular diseases: A review from bench to bed. Phytotherapy Research, Wiley, 2024.
• Daidzin improves the cisplatin chemosensitivity for osteosarcoma via binding to β-catenin protein and suppressing the Wnt pathway. Scientific Reports, Nature, 2025.
• Daidzin inhibits growth and induces apoptosis through the JAK2/STAT3 in human cervical cancer HeLa cells. PMC, 2021.
• No Clinically Relevant Pharmacokinetic Interactions of a Red Clover Dietary Supplement with Cytochrome P450 Enzymes in Women. PMC, 2021.
• Interaction of isoflavonoids with human liver microsomal cytochromes P450: inhibition of CYP enzyme activities. PubMed, 2016.
• Daidzein alleviates osteoporosis by promoting osteogenesis and angiogenesis coupling. PMC, 2023.
• Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells. PMC, 2015.
• Daidzein Prevents the Increase in CD4+CD28null T Cells and B Lymphopoesis in Ovariectomized Mice. PMC, 2011.
• Daidzin | C21H20O9 | CID 107971. PubChem, NIH.
• Daidzein | C15H10O4 | CID 5281708. PubChem, NIH.
• Daidzin | C21H20O9. ChemSpider.
• Kudzu (Pueraria mirifica/lobata). Townsend Letter.